Free Trial
LON:GCL

Geiger Counter 12/29/2025 Earnings Report

Geiger Counter logo
GBX 73 +0.50 (+0.69%)
As of 12:33 PM Eastern

Geiger Counter EPS Results

Actual EPS
-GBX 1.43
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Geiger Counter Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Geiger Counter Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Geiger Counter Earnings Headlines

NNVC FDA = New Momentum Wave!
NanoViricides (NYSE: NNVC) just received FDA Orphan Drug Designation for its antiviral NV-387, targeting measles at a time when no approved antiviral treatments exist and cases are resurging globally. Beyond measles, NV-387 is designed as a broad-spectrum platform targeting RSV, influenza, coronaviruses, Mpox, and more - giving NNVC exposure to multiple large markets as Phase II trials advance.tc pixel
Geiger Counter Ltd buys back 1 million shares
Geiger Counter Ltd announces share buyback
See More Geiger Counter Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Geiger Counter? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Geiger Counter and other key companies, straight to your email.

About Geiger Counter

A closed-end investment company investing in the exploration, development and production of uranium for nuclear energy.

View Geiger Counter Profile